These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 28844168)

  • 1. Effects of heart rate reduction with ivabradine on the international ındex of erectile function (IIEF-5) in patients with heart failure.
    Mert KU; Dural M; Mert GÖ; Iskenderov K; Özen A
    Aging Male; 2018 Jun; 21(2):93-98. PubMed ID: 28844168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ivabradine therapy on heart failure biomarkers.
    Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
    Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How does ivabradine effect erectile dysfunction in patients with heart failure?
    Aydın F; Bektur S; Taşdelen Y; Kıvrak Y; Hüseyinoglu Aydın A
    Kardiol Pol; 2017; 75(9):893-898. PubMed ID: 28541595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
    Das D; Savarese G; Dahlström U; Fu M; Howlett J; Ezekowitz JA; Lund LH
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28903983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
    Borer JS; Deedwania PC; Kim JB; Böhm M
    Am J Cardiol; 2016 Dec; 118(12):1948-1953. PubMed ID: 27780557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.
    Böhm M; Borer JS; Camm J; Ford I; Lloyd SM; Komajda M; Tavazzi L; Talajic M; Lainscak M; Reil JC; Ukena C; Swedberg K
    Eur J Heart Fail; 2015 May; 17(5):518-26. PubMed ID: 25801408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early NT-proBNP decrease with ivabradine in ambulatory patients with systolic heart failure.
    Sargento L; Satendra M; Longo S; Lousada N; Palma dos Reis R
    Clin Cardiol; 2013 Nov; 36(11):677-82. PubMed ID: 23929789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
    Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W
    Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients.
    Rogers JK; Kielhorn A; Borer JS; Ford I; Pocock SJ
    Curr Med Res Opin; 2015; 31(10):1903-9. PubMed ID: 26361063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
    Böhm M; Robertson M; Ford I; Borer JS; Komajda M; Kindermann I; Maack C; Lainscak M; Swedberg K; Tavazzi L
    Am J Cardiol; 2015 Dec; 116(12):1890-7. PubMed ID: 26508709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT.
    Böhm M; Komajda M; Borer JS; Ford I; Maack C; Tavazzi L; Moyne A; Swedberg K;
    Eur J Heart Fail; 2018 Feb; 20(2):373-381. PubMed ID: 29027329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to benefit of heart rate reduction with ivabradine in patients with heart failure and reduced ejection fraction.
    Böhm M; Abdin A; Slawik J; Mahfoud F; Borer J; Ford I; Swedberg K; Tavazzi L; Batailler C; Komajda M
    Eur J Heart Fail; 2023 Aug; 25(8):1429-1435. PubMed ID: 37092340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
    Tondi L; Fragasso G; Spoladore R; Pinto G; Gemma M; Slavich M; Godino C; Salerno A; Montanaro C; Margonato A
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):351-356. PubMed ID: 29762337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of ivabradine in Chinese patients with chronic heart failure: an observational study.
    Zhou J; Xu Y; Zheng Z; Zhang S; Yang J; Zhang Y; Tang B; Han H; Zhang Q; Liu F; Ding W; Qian C; Su G; Liu X; Shen Y; Shi B; Kong X; Ge Z; Zhang P; Guo X; Zhang H; Sun Y; Dong Y; Fu G; Feng L; Ge J;
    ESC Heart Fail; 2024 Apr; 11(2):846-858. PubMed ID: 38193606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial.
    Böhm M; Robertson M; Borer J; Ford I; Komajda M; Mahfoud F; Ewen S; Swedberg K; Tavazzi L
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial).
    Abdin A; Komajda M; Borer JS; Ford I; Tavazzi L; Batailler C; Swedberg K; Rosano GMC; Mahfoud F; Böhm M;
    ESC Heart Fail; 2023 Oct; 10(5):2895-2902. PubMed ID: 37427483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study.
    Ekman I; Chassany O; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L; Swedberg K
    Eur Heart J; 2011 Oct; 32(19):2395-404. PubMed ID: 21875859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
    Borer JS; Böhm M; Ford I; Robertson M; Komajda M; Tavazzi L; Swedberg K;
    Am J Cardiol; 2014 Feb; 113(3):497-503. PubMed ID: 24332674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure.
    Sallam M; Al-Saadi T; Alshekaili L; Al-Zakwani I
    Curr Vasc Pharmacol; 2016; 14(5):481-486. PubMed ID: 27145825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart rate reduction with ivabradine in patients with acute decompensated systolic heart failure.
    Sargento L; Satendra M; Longo S; Lousada N; dos Reis RP
    Am J Cardiovasc Drugs; 2014 Jun; 14(3):229-35. PubMed ID: 24452599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.